Nanobiotix S.A. (NBTX) rose 0.7% Thursday to $21.53, showing resilience as the broader biotechnology sector faced a downturn.
The stock's modest gain occurred without a specific company announcement or immediate catalyst identified within the last 48 hours.
| Current Price | $21.53 |
| Daily Change | +0.70% 🟢 |
| Day High / Low | $21.53 / $20.97 |
| 52-Week Range | $2.85 – $30.35 |
The performance is particularly notable given that the industry average declined about 1.6% today.
While NBTX is outperforming its peers in the short term, it follows a period of volatility where the stock fell roughly 7.5% between January 1 and January 13. According to MarketBeat, the stock recently received a consensus rating of “Hold” from analysts.
Market analysis suggests the current movement may be a stabilization following recent regulatory filings and neutral analyst updates.
Despite the quiet news cycle today, the stock remains a point of interest, fitting the profile of many growth stocks that have surged over the last 12 months.
Key Takeaways
- NBTX rose about 0.7% to $21.53 while the biotech sector dropped nearly 1.6%.
- Analysts issued a consensus “Hold” rating for the stock on January 14.
- A regulatory filing on January 13 disclosed over 48.4 million shares outstanding.
- The stock has gained more than 642% over the past year despite recent monthly declines.
- Major partners include Johnson & Johnson and MD Anderson for clinical programs.
Market Performance and Sector Comparison
NBTX's climb to $21.53 stands in contrast to its primary competitors.
For those learning how to read a stock quote, peers like Celldex Therapeutics, Inc. (CLDX) and Inhibrx Biosciences, Inc. (INBX) saw declines of over 3% and about 2.5% respectively.
Other industry players also struggled, with Immunocore Holdings plc (IMCR) dropping nearly 2% and RAPT Therapeutics, Inc. (RAPT) falling about 1.6%.
NBTX traded within a day range of $20.97 to $21.53, showing strength while the industry average slipped. This divergence suggests stock-specific interest, though the lack of new clinical data makes the exact driver of today's outperformance unclear.
| Company | Symbol | Daily Change | Industry Avg. Today |
|---|---|---|---|
| Nanobiotix S.A. | NBTX | +0.70% 🟢 | -1.58% 🔴 |
| RAPT Therapeutics, Inc. | RAPT | -1.58% 🔴 | -1.58% 🔴 |
| Immunocore Holdings plc | IMCR | -1.93% 🔴 | -1.58% 🔴 |
| Inhibrx Biosciences, Inc. | INBX | -2.52% 🔴 | -1.58% 🔴 |
| Celldex Therapeutics, Inc. | CLDX | -3.30% 🔴 | -1.58% 🔴 |
Recent Regulatory Disclosures
The most recent official activity from Nanobiotix was a mandatory regulatory filing on January 13, 2026. According to GlobeNewswire, the company disclosed its voting rights and share capital as of the end of 2025.
The filing reported 48,410,068 shares outstanding with total theoretical voting rights of 50,109,170. While such disclosures are routine for transparency and compliance under French rules, they occasionally coincide with minor price adjustments.
Understanding these filings is among the questions smart investors ask when evaluating corporate transparency.
Analyst Sentiment and Ratings
Market sentiment remains cautious despite the stock's daily gain. The “Hold” consensus rating issued on January 14 reflects a neutral outlook from the investment community, recommending that investors maintain their current positions.
This neutral stance is supported by a lack of intensive analyst scrutiny. Only two research reports have been issued on the company in the past 90 days.
The consensus suggests that while the company's long-term trajectory is significant, there may be a lack of immediate catalysts to drive a “Buy” recommendation at current price levels.
Long-Term Growth vs. Short-Term Volatility
While NBTX is up today, it has faced a challenging start to the year. The stock fell over 6% on January 5 and declined about 7.5% during the first two weeks of 2026, dropping from $23.12 on January 1 to $21.38 by mid-month.
However, the long-term perspective remains bullish for many investors. The stock has surged more than 642% over the last 12 months.
Over a six-month period, the gains exceed 312%, showcasing the massive rally Nanobiotix enjoyed throughout late 2025. This volatility is common for biotechnology firms, making it essential to use tools for analyzing price trends before entering a position.
| Time Period | Price Change | Performance |
|---|---|---|
| 1 Month | -5.15% | 🔴 |
| 3 Months | -23.73% | 🔴 |
| 6 Months | +312.22% | 🟢 |
| 1 Year | +642.41% | 🟢 |
Strategic Partnerships and Product Pipeline
Nanobiotix continues to rely on its high-profile collaborations to sustain its valuation. Investors tracking such complex biotech narratives often rely on the best stock analysis apps to monitor clinical progress.
The company is currently focused on JNJ-1900 (NBTXR3), its primary development candidate, through a partnership with Johnson & Johnson. Other key relationships include MD Anderson for sponsored trials and a $50 million royalty financing deal with HealthCare Royalty (HCRx).
These partnerships provide the financial and clinical backing necessary for its Phase 3 NANORAY-312 trial in head and neck cancer. Furthermore, the company is advancing its Curadigm Nanoprimer platform, which serves as a secondary technological pillar for the firm’s market position.
| 🟢 Bull Case | 🔴 Bear Case |
|---|---|
| • Strong outperformance of sector average today | • No immediate clinical or corporate catalyst |
| • Major partnerships with J&J and MD Anderson | • Neutral consensus “Hold” from analysts |
| • Massive 1-year growth exceeding 642% | • Significant short-term (YTD) price volatility |
The Bottom Line
Nanobiotix's ability to stay green during a sector-wide selloff highlights its relative strength, yet the lack of a clear catalyst today warrants caution.
The consensus “Hold” rating and recent monthly decline suggest that the stock may be entering a consolidation phase after its massive one-year rally.
Investors should monitor upcoming clinical trial updates and potential news regarding its partnership with Johnson & Johnson. Without new data, the stock's performance will likely continue to be influenced by broader biotech market conditions and its recent inclusion in major French indices like the CAC Mid 60.
